Sodium-Glucose Transporter 2 Inhibitors Concept

subject area of

• 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults  Journal Articles
• Sodium‐glucose co‐transporter‐2 inhibitors are associated with kidney benefits at all degrees of albuminuria: A retrospective cohort study of adults with diabetes  Journal Articles
• Addendum to Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes: 2015 Interim Update  Journal Articles
• Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials  Journal Articles
• CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis  Journal Articles
• Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum  Journal Articles
• Cardiovascular events and all‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta‐analysis of survival data  Journal Articles
• Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.  Journal Articles
• Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice  Journal Articles
• Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk  Journal Articles
• Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on cardiovascular and kidney outcomes in Asian versus White patients with type 2 diabetes mellitus  Journal Articles
• Efficacy and safety of dapagliflozin were similar in patients with type 2 DM and atherosclerotic CVD, regardless of PAD  Journal Articles
• Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial  Journal Articles
• Eligibility and Projected Benefits of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure  Journal Articles
• Exploring the Experiences of Adults With Type 2 Diabetes on Sodium Glucose Cotransporter 2 Inhibitors  Journal Articles
• Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease  Journal Articles
• Lowering of hemoglobin A1C and risk of cardiovascular outcomes and all-cause mortality, a meta-regression analysis  Journal Articles
• Management of mitochondrial diabetes in the era of novel therapies  Journal Articles
• Patient data from routinely collected medical records complement evidence from SGLT2 inhibitor outcome trials  Journal Articles
• Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes–2015 Interim Update  Journal Articles
• Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses  Journal Articles
• Reduction in heart failure outcomes with SGLT2 inhibitors irrespective of glycaemic status  Journal Articles
• SGLT2 inhibitors improved health status in Black and White patients with HF regardless of race  Journal Articles
• Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials  Journal Articles
• Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline.  Journal Articles
• Sodium‐Glucose Co‐Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials  Journal Articles
• Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure  Journal Articles
• Sodium–glucose cotransporter-2 inhibitors in patients without diabetes  Journal Articles
• Surgical and Advanced Medical Therapy for the Treatment of Type 2 Diabetes in Class I Obese Patients: a Short-Term Outcome  Journal Articles
• The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis  Journal Articles
• The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels  Journal Articles
• The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy  Journal Articles
• The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice  Journal Articles
• The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis  Journal Articles
• Use of sodium–glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study  Journal Articles
• Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review  Journal Articles